Biomind Labs Inc.
BMND
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -18.14% | 77.12% | |||
| Depreciation & Amortization | -- | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.70% | 22.03% | |||
| Operating Income | 19.70% | -22.03% | |||
| Income Before Tax | -74.40% | -138.77% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -74.40% | -138.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -74.40% | -138.77% | |||
| EBIT | 19.70% | -22.03% | |||
| EBITDA | 18.14% | -22.56% | |||
| EPS Basic | -66.67% | -140.91% | |||
| Normalized Basic EPS | 18.18% | -178.57% | |||
| EPS Diluted | -66.67% | -140.91% | |||
| Normalized Diluted EPS | 18.18% | -178.57% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||